Months af­ter steer­ing a seizure res­cue ther­a­py to mar­ket, UCB bags an­oth­er promis­ing late-stage as­set for $125M up­front

UCB has picked up an epilep­sy drug-de­vice from a buy­out that will cost at most $270 mil­lion, tuck­ing a Phase III-ready project and the team be­hind it to its grow­ing neu­rol­o­gy port­fo­lio.

While at least two ben­zo­di­azepines are al­ready avail­able as treat­ments for acute seizure, the Bel­gian phar­ma has been shop­ping for more con­ve­nient dos­ing meth­ods that could prove su­pe­ri­or to buc­cal mi­da­zo­lam and rec­tal di­azepam.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER